The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Celtic Sea Portfolio

26 Mar 2015 07:00

RNS Number : 4944I
Fastnet Oil & Gas PLC
26 March 2015
 

26 March 2015

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Celtic Sea Portfolio

- New Licensing Option Awarded, Existing Licensing Options and Deep Kinsale Option Extended

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focused on near-term exploration and appraisal acreage in Morocco and the Celtic Sea, is pleased to announce an update on its Celtic Sea portfolio.

 

Highlights:

· Award of new operated licensing option named the Ventry Licensing Option ("Ventry") in the North Celtic Sea Basin.

o 100% working interest in the Ventry Licensing Option covering 996 km2 over blocks 55/13 and part of blocks 55/7, 55/8, 55/12, 55/17, 55/18 and 55/19.

o Contiguous with and extending westwards from the previously awarded Mizzen Licensing Option 12/3 and East Mizzen Licensing Option 13/3.

o 18-month licensing option with the opportunity to extend, which requires the reprocessing of existing 2D seismic data and various geologic studies.

· Extension of existing licensing options: 13/3 ("East Mizzen"), 12/5 ("Shanagarry") and 12/6 ("Block 49/13") for a period of 18 months each.

o Work commitments include the reprocessing of existing seismic data and various geological studies.

· Extension of the Deep Kinsale Option with PSE Kinsale Energy Limited ("Kinsale Energy"), until 31st December 2015 which allows the Company to continue farm-in discussions with potential partners.

 

Carol Law, CEO of Fastnet, commented:

"This announcement marks the successful conclusion of a significant investment of Company time, expertise and resources in securing our attractive Celtic Sea acreage position, a highly prospective area that is increasingly becoming the focus of industry interest. Modern seismic processing and geological techniques have allowed us to better understand the development of the petroleum systems in the area and build a portfolio of attractive low risk prospects and leads with excellent project economics even in the current oil pricing environment.

We are delighted to add the Ventry Licensing Option to our portfolio, and believe it offers significant extension acreage with potential material upside on the west side of the large Mizzen structural prospect. We believe the western side of this large uplift will contain similar prospective stratigraphic features to those mapped on our 2013 3D seismic on the eastern flank of the Mizzen high and, in the event of exploration success in Mizzen and East Mizzen, we will be well positioned with running room on the plays.

"The extensions on our three existing prospective licence areas allows us to carry out the agreed work programmes, currently underway, which are economical and fully funded. The extension of the deadline to exercise the Deep Kinsale Option allows us to continue our farm-out discussions and is enhanced by the recent farm-in by Kinsale Energy to Lansdowne's nearby SEL 4/07.

"While we continue to evaluate opportunities for M&A in the current market environment, the Celtic Sea is very important to Fastnet and we see the potential to deliver significant shareholder value through developing this portfolio and attracting partners to pursue exploration activities."

Award of New Licensing Option

The Company has been notified by the Irish Department of Communications, Energy and Natural Resources (the "Department") that it has been awarded licensing option 15/1 covering blocks 55/13 and part blocks 55/7, 55/8, 55/12, 55/17, 55/18 and 55/19 in the North Celtic Sea Basin.

The newly named Ventry Licensing Option is valid from 1 March 2015 to 31st August 2016. It covers an area of 996 km2, and is contiguous with and extending westwards from the Company's previously awarded Mizzen Licensing Option 12/3 and East Mizzen Licensing Option 13/3. Fastnet is the designated operator and has a 100% working interest in the Ventry Licensing Option. The licensing option covers a period of 18 months and requires the reprocessing of existing 2D seismic data and various geological studies. Upon completing the work programme, the Company has the opportunity to extend the licensing option by a further 18 months. The Ventry Licensing Option provides extension acreage with significant running room for multiple play types which have been clearly imaged on Fastnet's Mizzen 3D seismic data, which was acquired in 2013.

 

Extension of Existing Licensing Options

The Company has separately been notified by the Department that existing Licensing Options have been extended as follows:

· Licensing Option East Mizzen, extended for a further 18 months from 1st November 2014 to 30th April 2016.

· Licensing Option Shanagarry extended for a further 18 months from 1st June 2014 to 30th November 2015.

· Licensing Option 12/6 ("Block 49/13") extended 15th May 2014 until 14th November 2015.

In each of the Licensing Option work programmes associated with the three Licensing Options, the Company is required to reprocess existing seismic data and carry out various geological studies. The Company may elect to apply to convert these options to Exploration Licences following these extension periods.

Extension of Deep Kinsale Option

The Company is pleased to announce that it has agreed to extend its Exclusive Option agreement with Kinsale Energy until 31st December 2015. This extended period will allow the Company to continue farm-in discussions with potential partners. There are no changes to the exclusive option agreement from those previously announced on 14th August 2014.

The "Deep Kinsale Prospect" area extends from 4,000 feet subsea below the producing Kinsale Head gas field and is defined as the "Deep Kinsale Sub-Area" of Petroleum Lease No. 1 (see map of the area on the Company's website: www.fastnetoilandgas.com/go/operations/ireland).

An updated corporate presentation is now available for download on the Company website via the following link: http://www.fastnetoilandgas.com/investor-relations/presentations

For further information please contact:

 

Fastnet Oil & Gas plc

+353 (1) 644 0007

Carol Law, Chief Executive Officer

Cathal Friel, Non-Executive Chairman

Shore Capital

+44 (0) 20 7408 4090

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

Camarco

+44 (0) 20 3757 4980

Billy Clegg, Georgia Mann, Ellie Reid

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLDMGZFLKVGKZM
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.